6.010USD-3.38%Mkt Cap: —P/E: —1d ago
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy fo…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value216.72M $
Revenue (TTM)25.52M $
Gross Profit-10.18M $
Net Income (TTM)-62.89M $
Revenue/Share0.4570 USD
Last Price6.010 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees226
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.68
EV/Revenue8.49
P/S—
P/B2.70
EPS (TTM)-0.81
EPS (Forward)—
52W Range
5.88030% of range6.320
52W High6.320 USD
52W Low5.880 USD
Profitability
Gross Margin-39.90%
Oper. Margin-119.97%
EBITDA Margin0.00%
Profit Margin-246.42%
ROE-43.13%
ROA-24.55%
Growth
Revenue Growth2745.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.44M $
CapEx (TTM)—
FCF Margin-287.61%
FCF Yield—
Net Debt-126.95M $
Net Debt/EBITDA1.57
Balance Sheet
Debt/Equity15.52
Current Ratio6.63
Quick Ratio6.32
Book Value/Sh2.238 USD
Cash/Share2.568 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.04:1
Split DateJul 5, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.47.94M
Float36.80M
Insiders16.49%
Institutions69.74%
Technical
SMA 506.102 (-1.5%)
SMA 2004.534 (+32.6%)
Beta1.34
S&P 52W Chg18.16%
Avg Vol (30d)2.74K
Avg Vol (10d)914
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—